Clinical Trial Update: TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435 [Phase 1]

View source ↗

Summary

Completed Phase 1 study assessing how severe renal impairment affects the pharmacokinetics and safety of TMC435 in Hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• TMC435

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Hepatitis C Virus | Phase 1 | Status: COMPLETED